Meet the Analyst: Dr. Tara Speranza, Bell Potter Analyst Part 2

The Bellcast
23/02/2023 13 min
Meet the Analyst: Dr. Tara Speranza, Bell Potter Analyst Part 2

Listen "Meet the Analyst: Dr. Tara Speranza, Bell Potter Analyst Part 2"

Descargar episodio

Episode Synopsis

Continue on to learn about the remaining stocks, Microba Life Sciences (ASX:MAP) and Monash IVF (ASX:MVF), as well as what to expect from these companies in 2023. In this video, Dr. Tara discusses:- (0:34) Impacts of Ferring's FDA approval on Microba- (5:30) Drivers behind Microba's increase in revenue - (7:12) What 2023 looks like for Monash IVF- (8:39) Monash IVF's rating- (11:45) Monash IVF's impact from legal actionNote: This interview was filmed on 7 February 2023.

More episodes of the podcast The Bellcast

From the Helm: Rural Funds Group (ASX:RFF), Tim Sheridan, COO & James Powell, GM 29/10/2025
From the helm: SenSen Networks Limited (ASX: SNS), Dr Subhash Challa, CEO 28/10/2025
From the helm: Bhagwan Marine Limited (ASX:BWN), Andrew Wackett, Director of Finance 30/09/2025
From the helm: Argenica Therapeutics (ASX:AGN), Dr. Liz Dallimore, CEO & MD 30/09/2025
From the helm: Cobram Estate Olives (ASX:CBO), Sam Beaton, Co-CEO 30/09/2025
From the helm: Metallium (ASX:MTM), Michael Walshe, CEO & MD 30/09/2025
From the helm: Metal Powder Works (ASX:MPW), John Barnes, Founder & MD 30/09/2025
From the helm: Cash Converters (ASX:CCV), Sam Budiselik, CEO & MD 30/09/2025
From the helm: Sports Entertainment Group (ASX:SEG), Craig Hutchison, CEO and Trent Bond, CFO 19/09/2025
From the helm: Cynata Therapeutics (ASX:CYP), Kilian Kelly, CEO 17/09/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA